The epidemiology of community acquired bacteremic pneumonia, due to streptococcus pneumoniae, in the top end of the northern territory, australia-over 22 years

Vaccine

Volumn 29, Issue 33, 2011, Pages 5386-5392

  Jacups, Susan P ^a,b   Cheng, Allen ^b,c  

^a CHARLES DARWIN UNIVERSITY   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Australia; Epidemiology; Indigenous; Pneumococcal vaccines; Pneumonia; Poverty; Prospective studies; Risk factors; Socioeconomic; Tropical medicine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; AUSTRALIA; BLOOD CULTURE; CIGARETTE SMOKING; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTHERN TERRITORY; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 79960381830     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.082     Document Type: Article

References (57)

1. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122(March (2)):130-141.
2. Murphy T.F. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. Clin Infect Dis 2008, 47(December (Suppl 3)):S145-S149.
3. Loeb M. Community-acquired pneumonia. Clin Evid (Online) 2008, 2008.
4. Diggins F.W. The true history of the discovery of penicillin, with refutation of the misinformation in the literature. Br J Biomed Sci 1999, 56(2):83-93.
5. Restrepo M.I., Anzueto A. Severe community-acquired pneumonia. Infect Dis Clin North Am 2009, 23(September (3)):503-520.
6. Welte T., Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009, 30(April (2)):127-135.
7. Welte T. Community-acquired pneumonia. Internist (Berl) 2009, 50(March (3)):331-339. quiz 40.
8. Torzillo P.J. Public health implications of pneumococcal disease in indigenous Australians. Aust N Z J Public Health 1997, 21(June (3)):243-244.
9. Australian Bureau of Statistics. The health and welfare of Australia's Aboriginal and Torres Strait Islander Peoples 2005. Canberra: Australian Bureau of Statistics, Australian Institute of Health and Welfare; 2005. Report No.: 4704.0.
10. Roche P.W., Krause V.L., Bartlett M., Coleman D., Cook H., Davis C., et al. Invasive pneumococcal disease in Australia, 2004. Commun Dis Intell 2006, 30(1):80-92.
11. Brotherton J., Wang H., Schaffer A., Quinn H., Menzies R., Hull B., et al. Vaccine preventable diseases and vaccination coverage in Australia 2003 to 2005. Commun Dis Intell 2007, 31:S55-S61.
12. Communicable Diseases Australia Notifications of pneumococcal disease (invasive) 2010, [cited 2010 9/11/2006]; Available from: www.health.gov.au/cda/Source/Rpt_4.cfm.
13. Turnidge J.D., Bell J.M., Collignon P.J. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Pneumococcal study group. Med J Aust 1999, 170(February (4)):152-155.
14. Australian Bureau of Statistics. Experimental estimates of Aboriginal and Torres Strait Islander Australians, Jun 2006. Canberra: Australian Bureau of Statistics; 2008. Report No.: 3238.0.55.001.
15. Australian Bureau of Statistics. Adult health: risk factors and socioeconomic status. Canberra: Australian Bureau of Statistics; 2010. Report No.: 4704.0.
16. Moberley S., Krause V., Cook H., Mulholland K., Carapetis J., Torzillo P., et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia. Vaccine 2010, 28(March (11)):2296-2301.
17. National Health and Medical Research Council. In: National Immunisation Handbook, 9th ed. Canberra: Australian Government, Department of Health and Ageing; 2008.
18. Krause V.L., Reid S.J., Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med J Aust 2000, 173(October):S27-S31.
19. Torzillo P.J., Hanna J.N., Morey F., Gratten M., Dixon J., Erlich J. Invasive pneumococcal disease in central Australia. Med J Aust 1995, 162(February (4)):182-186.
20. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2009, (4):CD000422.
21. Australian Bureau of Statistics. Regional population growth, Australia. Canberra: Australian Bureau of Statistics; 2010. Report No.: 3218.0.
22. Osborne J. Notes on the use of data transformations. Pract Assess Res Eval 2002, 8(6).
23. Torres A., Serra-Batlles J., Ferrer A., Jimenez P., Celis R., Cobo E., et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991, 144(August (2)):312-318.
24. Almirall J., Bolibar I., Balanzo X., Gonzalez C.A. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999, 13(February (2)):349-355.
25. Nuorti J.P., Butler J.C., Farley M.M., Harrison L.H., McGeer A., Kolczak M.S., et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. N Engl J Med 2000, 342(March (10)):681-689.
26. Padiglione A.A., Willis J., Bailey M., Fairley C.K. Characteristics of patients with community-acquired pneumococcal pneumonia. Med J Aust 1999, 170(February (4)):165-167.
27. Health Gains Planning: Department of Health and Families. Northern Territory resident population estimates by age, sex, indigenous status and health districts (1971-2009), using ABS Estimated Resident Population. Darwin; 2009.
28. Currie B.J., Jacups S.P., Cheng A.C., Fisher D.A., Anstey N.M., Huffam S.E., et al. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health 2004, 9(November (11)):1167-1174.
29. d'Espaignet ET, Measey ML, Dal Grande E. Northern Territory health and wellbeing survey, non-indigenous population, December 2000. Darwin: Epidemiology Unit, Health Gains Planning, Department of Health and Community Services; 2002.
30. Brimblecombe J., Mackerras D., Garnggulkpuy J., Maypilama E., Bundhala L., Dhurrkay R., et al. Leanness and type 2 diabetes in a population of indigenous Australians. Diabetes Res Clin Pract 2006, 72(April (1)):93-99.
31. Chondur R., Guthridge S. Smoking in the Northern Territory 2006, Health Gains Planning, Department of Health and Community Services, Darwin.
32. Merianos A., Patel M., Lane J.M., Noonan C.N., Sharrock D., Mock P.A., et al. The 1990-1991 outbreak of melioidosis in the Northern Territory of Australia: epidemiology and environmental studies. Southeast Asian J Trop Med Public Health 1993, 24(September (3)):425-435.
33. Hilbe J.M. Logistic regression models 2009, CRC Press, Tempe.
34. Singleton R.J., Butler J.C., Bulkow L.R., Hurlburt D., O'Brien K.L., Doan W., et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007, 25(March (12)):2288-2295.
35. Lieberman D. Atypical pathogens in community-acquired pneumonia. Clin Chest Med 1999, 20(September (3)):489-497.
36. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31(August (2)):347-382.
37. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(October (16)):2043-2051.
38. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
39. Mackenzie G., Carapetis J., Leach A.J., Hare K., Morris P. Indirect effects of childhood pneumococcal vaccination on pneumococcal carriage among adults and older children in Australian Aboriginal communities. Vaccine 2007, 25(March (13)):2428-2433.
40. Mackenzie G.A., Carapetis J.R., Morris P.S., Leach A.J. Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. J Paediatr Child Health 2005, 41(April (4)):201-208.
41. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297(April (16)):1784-1792.
42. Leach A.J., Morris P.S., McCallum G.B., Wilson C.A., Stubbs L., Beissbarth J., et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis 2009, 9:121.
43. Lister FS, Ordman D. The epidemiology of pneumonia on Witwatersrand Goldfields and the prevention of pneumonia and other allied acute respiratory diseases in native labourers in South Africa by means of vaccine. The South African Institute for Medical Research; 1935.
44. Gilbert G.L. Retreat of the pneumococcus?. Med J Aust 2000, 173(October):S20-S21.
45. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010, 16(3):217-225.
46. Mannino D.M., Davis K.J., Kiri V.A. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 2009, 103(February (2)):224-229.
47. Sheffield J.V., Root R.K. Smoking and pneumococcal infection. N Engl J Med 2000, 342(March (10)):732-734.
48. US Department of Health and Human Services. In: Healthy People 2010: understanding and improving health, 2nd ed. Washington DC: US Dept of Health and Human Services; 2000.
49. Parappil A., Depczynski B., Collett P., Marks G.B. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010, 15(August (6)):918-922.
50. Torzillo P.J., Pholeros P., Rainow S., Barker G., Sowerbutts T., Short T., et al. The state of health hardware in Aboriginal communities in rural and remote Australia. Aust N Z J Public Health 2008, 32(February (1)):7-11.
51. Ruiz M., Ewig S., Torres A., Arancibia F., Marco F., Mensa J., et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999, 160(September (3)):923-929.
52. Hanna J.N., Young D.M., Brookes D.L., Dostie B.G., Murphy D.M. The initial coverage and impact of the pneumococcal and influenza vaccination program for at-risk indigenous adults in Far North Queensland. Aust N Z J Public Health 2001, 25(December (6)):543-546.
53. Hanna J.N., Wenck D.J., Murphy D.N. Three fatal pneumococcal polysaccharide vaccine failures. Med J Aust 2000, 173(September (6)):305-307.
54. Hanna J.N., Gratten M., Tiley S.M., Brookes D.L., Bapty G. Pneumococcal vaccination: an important strategy to prevent pneumonia in Aboriginal and Torres Strait Island adults. Aust N Z J Public Health 1997, 21(June (3)):281-285.
55. Bliss S.J., Larzalere-Hinton F., Lacapa R., Eagle K.R., Frizzell F., Parkinson A., et al. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005. Arch Intern Med 2008, 168(April (7)):749-755.
56. Skull S.A., Nolan T.M. Australia needs an expanded immunisation register for further improvements in vaccine delivery and program evaluation. Med J Aust 2007, 187(November (9)):504-505.
57. Cheng A.C., Hobbs C.M., Robinson P.M. Australia needs an expanded immunisation register. Med J Aust 2008, 188(February (4)):263.